Cargando…

Elucidation of novel compounds and epitope-based peptide vaccine design against C30 endopeptidase regions of SARS-CoV-2 using immunoinformatics approaches

There has been progressive improvement in immunoinformatics approaches for epitope-based peptide design. Computational-based immune-informatics approaches were applied to identify the epitopes of SARS-CoV-2 to develop vaccines. The accessibility of the SARS-CoV-2 protein surface was analyzed, and he...

Descripción completa

Detalles Bibliográficos
Autores principales: Marriam, Saigha, Afghan, Muhammad Sher, Nadeem, Mazhar, Sajid, Muhammad, Ahsan, Muhammad, Basit, Abdul, Wajid, Muhammad, Sabri, Sabeen, Zafar, Imran, Rashid, Summya, Sehgal, Sheikh Arslan, Alkhalifah, Dalal Hussien M., Hozzein, Wael N., Chen, Kow-Tong, Sharma, Rohit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10244718/
https://www.ncbi.nlm.nih.gov/pubmed/37293206
http://dx.doi.org/10.3389/fcimb.2023.1134802
_version_ 1785054704500211712
author Marriam, Saigha
Afghan, Muhammad Sher
Nadeem, Mazhar
Sajid, Muhammad
Ahsan, Muhammad
Basit, Abdul
Wajid, Muhammad
Sabri, Sabeen
Sajid, Muhammad
Zafar, Imran
Rashid, Summya
Sehgal, Sheikh Arslan
Alkhalifah, Dalal Hussien M.
Hozzein, Wael N.
Chen, Kow-Tong
Sharma, Rohit
author_facet Marriam, Saigha
Afghan, Muhammad Sher
Nadeem, Mazhar
Sajid, Muhammad
Ahsan, Muhammad
Basit, Abdul
Wajid, Muhammad
Sabri, Sabeen
Sajid, Muhammad
Zafar, Imran
Rashid, Summya
Sehgal, Sheikh Arslan
Alkhalifah, Dalal Hussien M.
Hozzein, Wael N.
Chen, Kow-Tong
Sharma, Rohit
author_sort Marriam, Saigha
collection PubMed
description There has been progressive improvement in immunoinformatics approaches for epitope-based peptide design. Computational-based immune-informatics approaches were applied to identify the epitopes of SARS-CoV-2 to develop vaccines. The accessibility of the SARS-CoV-2 protein surface was analyzed, and hexa-peptide sequences (KTPKYK) were observed having a maximum score of 8.254, located between amino acids 97 and 102, whereas the FSVLAC at amino acids 112 to 117 showed the lowest score of 0.114. The surface flexibility of the target protein ranged from 0.864 to 1.099 having amino acid ranges of 159 to 165 and 118 to 124, respectively, harboring the FCYMHHM and YNGSPSG hepta-peptide sequences. The surface flexibility was predicted, and a 0.864 score was observed from amino acids 159 to 165 with the hepta-peptide (FCYMHHM) sequence. Moreover, the highest score of 1.099 was observed between amino acids 118 and 124 against YNGSPSG. B-cell epitopes and cytotoxic T-lymphocyte (CTL) epitopes were also identified against SARS-CoV-2. In molecular docking analyses, -0.54 to -26.21 kcal/mol global energy was observed against the selected CTL epitopes, exhibiting binding solid energies of -3.33 to -26.36 kcal/mol. Based on optimization, eight epitopes (SEDMLNPNY, GSVGFNIDY, LLEDEFTPF, DYDCVSFCY, GTDLEGNFY, QTFSVLACY, TVNVLAWLY, and TANPKTPKY) showed reliable findings. The study calculated the associated HLA alleles with MHC-I and MHC-II and found that MHC-I epitopes had higher population coverage (0.9019% and 0.5639%) than MHC-II epitopes, which ranged from 58.49% to 34.71% in Italy and China, respectively. The CTL epitopes were docked with antigenic sites and analyzed with MHC-I HLA protein. In addition, virtual screening was conducted using the ZINC database library, which contained 3,447 compounds. The 10 top-ranked scrutinized molecules (ZINC222731806, ZINC077293241, ZINC014880001, ZINC003830427, ZINC030731133, ZINC003932831, ZINC003816514, ZINC004245650, ZINC000057255, and ZINC011592639) exhibited the least binding energy (-8.8 to -7.5 kcal/mol). The molecular dynamics (MD) and immune simulation data suggest that these epitopes could be used to design an effective SARS-CoV-2 vaccine in the form of a peptide-based vaccine. Our identified CTL epitopes have the potential to inhibit SARS-CoV-2 replication.
format Online
Article
Text
id pubmed-10244718
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102447182023-06-08 Elucidation of novel compounds and epitope-based peptide vaccine design against C30 endopeptidase regions of SARS-CoV-2 using immunoinformatics approaches Marriam, Saigha Afghan, Muhammad Sher Nadeem, Mazhar Sajid, Muhammad Ahsan, Muhammad Basit, Abdul Wajid, Muhammad Sabri, Sabeen Sajid, Muhammad Zafar, Imran Rashid, Summya Sehgal, Sheikh Arslan Alkhalifah, Dalal Hussien M. Hozzein, Wael N. Chen, Kow-Tong Sharma, Rohit Front Cell Infect Microbiol Cellular and Infection Microbiology There has been progressive improvement in immunoinformatics approaches for epitope-based peptide design. Computational-based immune-informatics approaches were applied to identify the epitopes of SARS-CoV-2 to develop vaccines. The accessibility of the SARS-CoV-2 protein surface was analyzed, and hexa-peptide sequences (KTPKYK) were observed having a maximum score of 8.254, located between amino acids 97 and 102, whereas the FSVLAC at amino acids 112 to 117 showed the lowest score of 0.114. The surface flexibility of the target protein ranged from 0.864 to 1.099 having amino acid ranges of 159 to 165 and 118 to 124, respectively, harboring the FCYMHHM and YNGSPSG hepta-peptide sequences. The surface flexibility was predicted, and a 0.864 score was observed from amino acids 159 to 165 with the hepta-peptide (FCYMHHM) sequence. Moreover, the highest score of 1.099 was observed between amino acids 118 and 124 against YNGSPSG. B-cell epitopes and cytotoxic T-lymphocyte (CTL) epitopes were also identified against SARS-CoV-2. In molecular docking analyses, -0.54 to -26.21 kcal/mol global energy was observed against the selected CTL epitopes, exhibiting binding solid energies of -3.33 to -26.36 kcal/mol. Based on optimization, eight epitopes (SEDMLNPNY, GSVGFNIDY, LLEDEFTPF, DYDCVSFCY, GTDLEGNFY, QTFSVLACY, TVNVLAWLY, and TANPKTPKY) showed reliable findings. The study calculated the associated HLA alleles with MHC-I and MHC-II and found that MHC-I epitopes had higher population coverage (0.9019% and 0.5639%) than MHC-II epitopes, which ranged from 58.49% to 34.71% in Italy and China, respectively. The CTL epitopes were docked with antigenic sites and analyzed with MHC-I HLA protein. In addition, virtual screening was conducted using the ZINC database library, which contained 3,447 compounds. The 10 top-ranked scrutinized molecules (ZINC222731806, ZINC077293241, ZINC014880001, ZINC003830427, ZINC030731133, ZINC003932831, ZINC003816514, ZINC004245650, ZINC000057255, and ZINC011592639) exhibited the least binding energy (-8.8 to -7.5 kcal/mol). The molecular dynamics (MD) and immune simulation data suggest that these epitopes could be used to design an effective SARS-CoV-2 vaccine in the form of a peptide-based vaccine. Our identified CTL epitopes have the potential to inhibit SARS-CoV-2 replication. Frontiers Media S.A. 2023-05-24 /pmc/articles/PMC10244718/ /pubmed/37293206 http://dx.doi.org/10.3389/fcimb.2023.1134802 Text en Copyright © 2023 Marriam, Afghan, Nadeem, Sajid, Ahsan, Basit, Wajid, Sabri, Sajid, Zafar, Rashid, Sehgal, Alkhalifah, Hozzein, Chen and Sharma https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cellular and Infection Microbiology
Marriam, Saigha
Afghan, Muhammad Sher
Nadeem, Mazhar
Sajid, Muhammad
Ahsan, Muhammad
Basit, Abdul
Wajid, Muhammad
Sabri, Sabeen
Sajid, Muhammad
Zafar, Imran
Rashid, Summya
Sehgal, Sheikh Arslan
Alkhalifah, Dalal Hussien M.
Hozzein, Wael N.
Chen, Kow-Tong
Sharma, Rohit
Elucidation of novel compounds and epitope-based peptide vaccine design against C30 endopeptidase regions of SARS-CoV-2 using immunoinformatics approaches
title Elucidation of novel compounds and epitope-based peptide vaccine design against C30 endopeptidase regions of SARS-CoV-2 using immunoinformatics approaches
title_full Elucidation of novel compounds and epitope-based peptide vaccine design against C30 endopeptidase regions of SARS-CoV-2 using immunoinformatics approaches
title_fullStr Elucidation of novel compounds and epitope-based peptide vaccine design against C30 endopeptidase regions of SARS-CoV-2 using immunoinformatics approaches
title_full_unstemmed Elucidation of novel compounds and epitope-based peptide vaccine design against C30 endopeptidase regions of SARS-CoV-2 using immunoinformatics approaches
title_short Elucidation of novel compounds and epitope-based peptide vaccine design against C30 endopeptidase regions of SARS-CoV-2 using immunoinformatics approaches
title_sort elucidation of novel compounds and epitope-based peptide vaccine design against c30 endopeptidase regions of sars-cov-2 using immunoinformatics approaches
topic Cellular and Infection Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10244718/
https://www.ncbi.nlm.nih.gov/pubmed/37293206
http://dx.doi.org/10.3389/fcimb.2023.1134802
work_keys_str_mv AT marriamsaigha elucidationofnovelcompoundsandepitopebasedpeptidevaccinedesignagainstc30endopeptidaseregionsofsarscov2usingimmunoinformaticsapproaches
AT afghanmuhammadsher elucidationofnovelcompoundsandepitopebasedpeptidevaccinedesignagainstc30endopeptidaseregionsofsarscov2usingimmunoinformaticsapproaches
AT nadeemmazhar elucidationofnovelcompoundsandepitopebasedpeptidevaccinedesignagainstc30endopeptidaseregionsofsarscov2usingimmunoinformaticsapproaches
AT sajidmuhammad elucidationofnovelcompoundsandepitopebasedpeptidevaccinedesignagainstc30endopeptidaseregionsofsarscov2usingimmunoinformaticsapproaches
AT ahsanmuhammad elucidationofnovelcompoundsandepitopebasedpeptidevaccinedesignagainstc30endopeptidaseregionsofsarscov2usingimmunoinformaticsapproaches
AT basitabdul elucidationofnovelcompoundsandepitopebasedpeptidevaccinedesignagainstc30endopeptidaseregionsofsarscov2usingimmunoinformaticsapproaches
AT wajidmuhammad elucidationofnovelcompoundsandepitopebasedpeptidevaccinedesignagainstc30endopeptidaseregionsofsarscov2usingimmunoinformaticsapproaches
AT sabrisabeen elucidationofnovelcompoundsandepitopebasedpeptidevaccinedesignagainstc30endopeptidaseregionsofsarscov2usingimmunoinformaticsapproaches
AT sajidmuhammad elucidationofnovelcompoundsandepitopebasedpeptidevaccinedesignagainstc30endopeptidaseregionsofsarscov2usingimmunoinformaticsapproaches
AT zafarimran elucidationofnovelcompoundsandepitopebasedpeptidevaccinedesignagainstc30endopeptidaseregionsofsarscov2usingimmunoinformaticsapproaches
AT rashidsummya elucidationofnovelcompoundsandepitopebasedpeptidevaccinedesignagainstc30endopeptidaseregionsofsarscov2usingimmunoinformaticsapproaches
AT sehgalsheikharslan elucidationofnovelcompoundsandepitopebasedpeptidevaccinedesignagainstc30endopeptidaseregionsofsarscov2usingimmunoinformaticsapproaches
AT alkhalifahdalalhussienm elucidationofnovelcompoundsandepitopebasedpeptidevaccinedesignagainstc30endopeptidaseregionsofsarscov2usingimmunoinformaticsapproaches
AT hozzeinwaeln elucidationofnovelcompoundsandepitopebasedpeptidevaccinedesignagainstc30endopeptidaseregionsofsarscov2usingimmunoinformaticsapproaches
AT chenkowtong elucidationofnovelcompoundsandepitopebasedpeptidevaccinedesignagainstc30endopeptidaseregionsofsarscov2usingimmunoinformaticsapproaches
AT sharmarohit elucidationofnovelcompoundsandepitopebasedpeptidevaccinedesignagainstc30endopeptidaseregionsofsarscov2usingimmunoinformaticsapproaches